The website may be down at times on Saturday, December 14, and Sunday, December 15, for maintenance. 

brand logo

Am Fam Physician. 1998;58(5):1084

Table 1 of the article “Combination Anti-retroviral Therapy for HIV Infection” (June 1998, p. 2791) contained an editing error. Dosing recommendations for zalcitabine (ddC: Hivid) would only include a dose reduction for weight under 60 kg in patients who have developed peripheral neuropathy attributed to zalcitabine therapy. Table 4 of the same article also contained an error. The Invirase formulation of saquinavir should not have been included. The corrected table is reprinted here.

Preferred initial regimen
Two nucleoside analogs + a highly active protease inhibitor, such as ritonavir (Norvir), indinavir (Crixivan), nelfinavir (Viracept) or saquinavir (Fortovase)
Alternative initial regimens
Two nucleoside analogs + a nonnucleoside reverse transcriptase inhibitor
Two nucleoside analogs + saquinavir
Two nucleoside analogs (although not generally recommended)
Regimens not recommended
Monotherapy
Stavudine (Zerit) + zidovudine (Retrovir)
Zalcitabine (Hivid) + didanosine (Videx)
Zalcitabine + stavudine
Zalcitabine + lamivudine (Epivir)
Suggested regimens for patients who fail to respond to initial therapy
• If initial regimen was two nucleoside analogs and a protease inhibitor, change to one of the following:
Two different nucleoside analogs + a different protease inhibitor
Two different nucleoside analogs + a protease inhibitor combination
Two different nucleoside analogs + a protease inhibitor + a nonnucleoside reverse transcriptase inhibitor
• If initial regimen was two nucleoside analogs and a nonnucleoside reverse transcriptase inhibitor, change to the following:
Two different nucleoside analogs + a protease inhibitor
• If initial regimen was two nucleoside analogs, change to the following:
Two different nucleoside analogs + a protease inhibitor
• If initial regimen was one nucleoside analog, change to one of the following:
Two different nucleoside analogs + a protease inhibitor
Two different nucleoside analogs + a nonnucleoside reverse transcriptase inhibitor

Continue Reading


More in AFP

Copyright © 1998 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.